148 related articles for article (PubMed ID: 36867373)
1. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology.
Yildirim HC; Guven DC; Akyildiz A; Yalcin S; Dizdar O
Ir J Med Sci; 2023 Dec; 192(6):2631-2634. PubMed ID: 36867373
[TBL] [Abstract][Full Text] [Related]
2. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
3. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
[TBL] [Abstract][Full Text] [Related]
4. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis.
Zhou ML; Kang M; Li GC; Guo XM; Zhang Z
World J Surg Oncol; 2016 Aug; 14(1):209. PubMed ID: 27502921
[TBL] [Abstract][Full Text] [Related]
5. Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis.
Lu H; Sun Y; Zhu Z; Yao J; Xu H; Huang R; Huang B
Ann Surg Oncol; 2022 Oct; 29(11):6962-6975. PubMed ID: 35723792
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
Kilic L; Ordu C; Ekenel M; Yildiz I; Keskin S; Sen F; Gural Z; Asoglu O; Kizir A; Aykan F
Med Oncol; 2013; 30(3):660. PubMed ID: 23877872
[TBL] [Abstract][Full Text] [Related]
7. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis.
Huang YY; Yang Q; Zhou SW; Wei Y; Chen YX; Xie DR; Zhang B
PLoS One; 2013; 8(7):e68939. PubMed ID: 23874819
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
9. Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection: A Retrospective Study.
Li Q; Li G; Palmer JD; Zhang Z
Am J Clin Oncol; 2017 Aug; 40(4):375-380. PubMed ID: 25503428
[TBL] [Abstract][Full Text] [Related]
10. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Park SH; Lim DH; Sohn TS; Lee J; Zang DY; Kim ST; Kang JH; Oh SY; Hwang IG; Ji JH; Shin DB; Yu JI; Kim KM; An JY; Choi MG; Lee JH; Kim S; Hong JY; Park JO; Park YS; Lim HY; Bae JM; Kang WK;
Ann Oncol; 2021 Mar; 32(3):368-374. PubMed ID: 33278599
[TBL] [Abstract][Full Text] [Related]
12. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer.
Wu HC; Lin WL; Lin CL; Lin CY; Chen SW; Chen YX; Chen CH; Lee SW; Chen SH; Tsao CJ; Huang WT; Guo HR
Aging (Albany NY); 2021 Jul; 13(13):17337-17348. PubMed ID: 34226296
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
[TBL] [Abstract][Full Text] [Related]
14. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy.
Jácome AA; Wohnrath DR; Scapulatempo Neto C; Fregnani JH; Quinto AL; Oliveira AT; Vazquez VL; Fava G; Martinez EZ; Santos JS
Gastric Cancer; 2013 Apr; 16(2):233-8. PubMed ID: 22740060
[TBL] [Abstract][Full Text] [Related]
16. Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy.
Li Y; Zhu Z; Ma F; Xue L; Tian Y
Cancer Med; 2020 Sep; 9(18):6617-6628. PubMed ID: 32744431
[TBL] [Abstract][Full Text] [Related]
17. Can adjuvant chemoradiotherapy replace extended lymph node dissection in gastric cancer?
Jansen EP; Boot H; van de Velde CJ; van Sandick J; Cats A; Verheij M
Recent Results Cancer Res; 2012; 196():229-40. PubMed ID: 23129378
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center.
Costa WL; Coimbra FJ; Fogaroli RC; Ribeiro HS; Diniz AL; Begnami MD; Mello CA; Fanelli MF; Silva MJ; Fregnani JH; Montagnini AL
Radiat Oncol; 2012 Oct; 7():169. PubMed ID: 23068190
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: is radiotherapy necessary after D2-dissection?
Chang JS; Koom WS; Lee Y; Yoon HI; Lee HS
World J Gastroenterol; 2014 Sep; 20(36):12900-7. PubMed ID: 25278687
[TBL] [Abstract][Full Text] [Related]
20. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
